EditorÐWe were interested to read the article by Jeffs and colleagues 1 on the addition of clonidine to morphine PCA devices, and would like to make some comments. First, the median pain score in the morphine group for the ®rst 12 h was given as 3 with a range of 1±4, although it was stated that the pain scale used was 0±3. If this should be read as a median of 2 with a range of 1±3, it suggests that these patients experienced signi®cant pain and we wondered if any rescue analgesia was given after the initial boluses of morphine in recovery.
Second, in a recent study by Marinangeli and colleagues 2 the optimum analgesic dose of clonidine in the postoperative period was found to be a 3 mg kg ±1 bolus followed by an infusion of 0.3 mg kg ±1 h ±1 . This was shown to signi®cantly decrease morphine PCA requirements, although the study only lasted for 12 h. The rate of infusion used equated to 21 mg h ±1 in a 70 kg adult, compared with an average clonidine dose equivalent to 40 mg h ±1 over the entire duration of this study (together with morphine 72 mg over 36 h in the clonidine group). Thus, the patients in this study received approximately twice the average hourly dose of clonidine compared to Marinangeli's study, and there was no reduction in morphine requirements in the ®rst 12 h. The current study therefore does not support Marinangeli's data and, as the authors stated, checking plasma concentrations may add useful information in trying to optimize the dose delivered in each PCA bolus.
We also note that patients in this study were given droperidol 1 mg at induction of anaesthesia. Droperidol is a butyrophenone agent with a variety of actions and, of particular relevance to this study, is known to have alpha-antagonist effects.
3 It is therefore possible that droperidol may have a signi®cant interaction with the effects of clonidine at alpha-receptors that would affect the results of this study.
Finally, the scoring systems used by the investigators seem to have been devised de novo for this study. Scoring systems, especially for subjective measurements such as pain and sedation, should be validated before use in a trial such as this one and we wondered whether this had occurred.
C. Carey S. Jaggar London, UK EditorÐThank you for allowing us to reply to the letter by Drs Carey and Jaggar. We would ®rst like to apologize for an error in Table 2 . As they rightly say, the median pain score in the morphine group for the ®rst 12 h should read 2 with a range of 1±3. Rescue analgesia was not given, but the patients were encouraged to use their PCA.
With regard to our use of droperidol, it was given to both groups at induction only. We would therefore expect any difference in our ®ndings to be because of the clonidine and not the droperidol.
We agree that our scoring system had not been validated and, whilst we agree this would have been optimal, this scoring system was chosen as it is the one used on our PCA/pain charts. It was felt that less confusion would occur if a scoring system familiar to the ward staff was used. S. A. Jeffs J. E. Hall S. Morris Cardiff, UK 
Propofol and myocardial lipid peroxidation
EditorÐThe recent article by Sayin and colleagues 1 well demonstrates decreased peroxidation in patients undergoing cardiac surgery receiving an infusion of propofol rather than fentanyl. Despite the well known injurious effects of free radicals when formed in large quantities during ischaemia/reperfusion, I think that their recommendation for the use of propofol`in an anaesthetic drug regimen during CABG if ischaemia and reperfusion injury is of concern' should carry an important caveat based on recent ®ndings. Indeed, a contrary conclusion could be drawn. Free radicals are certainly injurious in large quantities. However, there is now considerable evidence that they are essential mediators in clinically important endogenous pathways of cardioprotection.
2±5 Scavenging of free radicals before ischaemia may impede the heart's innate ability to protect itself from the effects of ischaemia/reperfusion; this has been demonstrated in terms of myocardial stunning, arrhythmias and infarction. It may account for the failure of several clinical trials to demonstrate a bene®t of scavengers given before ischaemia. Laboratory reports describe abrogation of cardioprotection when radicals are scavenged; this applies to protection effected by ischaemic preconditioning, 2 by endogenous substances, 3 and by volatile anaesthetic agents. 4 In humans, even transient exposure to iso¯urane has been shown to induce a state of cardioprotection; 6 this occurs by a mechanism that is believed to be free radical mediated.
4 5 A recent clinical trial compared propofol with sevo¯urane in cardiac surgery patients; 7 using left ventricular function and troponin as markers of cardiac injury, sevo¯urane, but not propofol, was found to be cardioprotective. Generation of free radicals by volatile anaesthetics, 4 and scavenging of free radicals by propofol, may account for this difference. Unfortunately, the study by Sayin and colleagues 1 does not report these or other indices of cardiac injury. Finally, it is important to note that opioids have been shown to generate free radicals in the heart. 3 8 L. G. Kevin Milwaukee, USA EditorÐWe appreciate Dr Kevin's comments on our article on propofol decreasing lipid peroxidation during cardiopulmonary bypass.
1 In his letter he claimed that our recommendation about the use of propofol during CABG where ischaemia and reperfusion is of concern, could be rebutted by the recent view that free radicals are important mediators for ischaemic preconditioning, leading to better ventricular function after bypass. Free radicals may have contrasting opposite effects when produced during bene®cial ischaemic preconditioning or during prolonged and deleterious ischaemia and reperfusion, 9 but they are not considered to be the only trigger for ischaemic preconditioning.
10 Activation of the kinase cascade is thought to be a key feature of preconditioning signals.
11 Although better Correspondence
